How to prevent fractures in the individual with osteoporosis

Best Practice and Research: Clinical Rheumatology

Volumn 15, Issue 3, 2001, Pages 497-515

  Javaid, M K ^a   Cooper, C ^a  

^a UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

Author keywords

Bisphosphonate; Calcium; Fracture; Osteoporosis; SERM; Vitamin D

Indexed keywords

ALENDRONIC ACID; ANABOLIC AGENT; CALCITONIN; CALCITRIOL; CALCIUM; COLECALCIFEROL; CORTICOSTEROID; ESTROGEN; ETIDRONIC ACID; FLUORIDE SODIUM; GLUCOCORTICOID; PARATHYROID HORMONE; PHOSPHONIC ACID DERIVATIVE; PLACEBO; RALOXIFENE; RISEDRONIC ACID; SELECTIVE ESTROGEN RECEPTOR MODULATOR; TAMOXIFEN; TIBOLONE; VITAMIN D;

BONE ATROPHY; BREAST CANCER; CLINICAL TRIAL; DIAGNOSTIC VALUE; DIET SUPPLEMENTATION; DRUG EFFECT; DUAL ENERGY X RAY ABSORPTIOMETRY; ENDOMETRIUM CANCER; ESTROGEN THERAPY; EXERCISE; FRACTURE; GASTROINTESTINAL SYMPTOM; HEALTH CARE COST; HIP FRACTURE; HUMAN; HYPERCALCEMIA; INCIDENCE; KIDNEY CALCIFICATION; KIDNEY FAILURE; LIFESTYLE; LONG TERM CARE; METABOLIC DISORDER; MORBIDITY; MORTALITY; OSTEOLYSIS; OSTEOPOROSIS; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROPHYLAXIS; REVIEW; RISK ASSESSMENT; SMOKING CESSATION; THROMBOEMBOLISM; TREATMENT OUTCOME; VERTEBRA FRACTURE;

EID: 0034877260     PISSN: 15216942     EISSN: None     Source Type: Journal    
DOI: 10.1053/berh.2001.0163     Document Type: Article

References (76)

1. Which fractures are associated with low appendicular bone mass in elderly women? The Study of Osteoporotic Fractures Research Group
2. Prevalence and incidence of vertebral deformities
3. Health impact associated with vertebral deformities: Results from the European Vertebral Osteoporosis Study (EVOS)
4. Majority of hip fractures occur as a result of a fall and impact on the greater trochanter of the femur: A prospective controlled hip fracture study with 206 consecutive patients
5. Hip fractures: Incidence, risk factors, energy absorption, and prevention
6. Evidence-based medicine and osteoporosis: A comparison of fracture risk reduction data from osteoporosis randomised clinical trials
7. A meta-analysis of cigarette smoking, bone mineral density and risk of hip fracture: Recognition of a major effect
8. Ex-smokers and risk of hip fracture
9. Smoking, smoking cessation, and risk of hip fracture in women
10. Fractures and lifestyle: Effect of cigarette smoking, alcohol intake, and relative weight on the risk of hip and forearm fractures in middle-aged women
11. Smoking eliminates the protective effect of oral estrogens on the risk for hip fracture among women
12. Effect of two randomised exercise programmes on bpone mass of healthy postmenopausal women
13. Physical activity and predisposition for hip fractures: A review
14. Evaluation of a program for rehabilitation of osteoporotic patients (PRO): 4-year follow-up. The Bone and Mineral Group of the University of Toronto
15. Home exercise to improve strength and walking velocity after hip fracture: A randomized controlled trial
16. The value of early mobilisation in the treatment of Colles' fractures
17. A multifactorial intervention to reduce the risk of falling among elderly people living in the community
18. Effect of external hip protectors on hip fractures
19. Physical activity, muscle strength, and calcium intake in fracture of the proximal femur in Britain
20. Concurrent axial and appendicular osteoporosis: Its relation to calcium consumption
21. Calcium nutrition and its implications for osteoporosis. Part II. After menopause
22. Correcting calcium nutritional deficiency prevents spine fractures in elderly women
23. Evidence for efficacy of drugs affecting bone metabolism in preventing hip fracture
24. Calcium for the prevention of osteoporotic fractures in post-menopausal women
25. Calcitriol in the treatment of postmenopausal osteoporosis
26. Postmenopausal osteoporosis: No affect of three years treatment with 1,25-dihydroxycholecalciferol
27. Vitamin D3 and calcium to prevent hip fractures in the elderly women
28. Effect of calcium and cholecalciferol treatment for three years on hip fractures in elderly women
29. Annual injection of vitamin D and fractures of aged bones
30. Influence of age and body mass on the effects of vitamin D on hip fracture risk
31. Treatment of postmenopausal osteoporosis with transdermal estrogen
32. Hip fracture and the use of estrogens in postmenopausal women. The Framingham Study
33. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/Progestin Replacement Study (HERS) Research
34. Cardioprotective effect of hormone replacement therapy in postmenopausal women: Is the evidence biased?
35. Hip and calcaneal bone loss increase with advancing age: Longitudinal results from the study of osteoporotic fractures
36. Does estrogen adequately protect postmenopausal women against osteoporosis: An iconoclastic perspective
37. Postmenopausal hormone therapy increases risk for venous thromboembolic disease. The Heart and Estrogen/progestin Replacement Study
38. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxefene: Results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators
39. The effect of raloxifene on risk of breast cancer in postmenopausal women: Results from the MORE randomized trial. Multiple Outcomes of Raloxifene Evaluation
40. Effects of raloxifene on bone mineral density, serum cholesterol concentrations, and uterine endometrium in postmenopausal women
41. A randomized study of tibolone on bone mineral density in osteoporotic postmenopausal women with previous fractures
42. Bone mass homeostasis and bisphosphonate action
43. Four-year study of intermittent cyclic etidronate treatment of postmenopausal osteoporosis: Three years of blinded therapy followed by one year of open therapy
44. A pooled data analysis on the use of intermittent cyclical etidronate therapy for the prevention and treatment of corticosteroid induced bone loss
45. Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. The Alendronate Phase III Osteoporosis Treatment Study Group
46. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group
47. Multinational, placebo-controlled, randomized trial of the effects of alendronate on bone density and fracture risk in postmenopausal women with low bone mass: Results of the FOSIT study. Foxamax International Trial Study Group
48. Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: Results from the Fracture Intervention Trial
49. Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: A randomized controlled trial. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group
50. Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group
51. Randomised trial of the effects of risedronate on vertebral fractures in women with established post-menopausal osteoporosis
52. Skeletal benefits of alendronate: 7-year treatment of postmenopausal osteoporotic women. Phase III Osteoporosis Treatment Study Group
53. A four-year randomized controlled trial of hormone replacement and bisphosphonate, alone or in combination, in women with postmenopausal osteoporosis
54. Addition of alendronate to ongoing hormone replacement therapy in the treatment of osteoporosis: A randomized, controlled clinical trial
55. Effects of oral alendronate and intranasal salmon calcitonin on bone mass and biochemical markers of bone turnover in postmenopausal women with osteoporosis
56. A randomized trial of nasal spray salmon calcitonin in postmenopausal women with established osteoporosis: The prevent recurrence of osteoporotic fractures study
57. What proof proves about calcitonin and clinical trials
58. Total and regional bone mineral content and fracture rate in postmenopausal osteoporosis treated with salmon calcitonin: A prospective study
59. Effects of salcatonin given intranasally on bone mass and fracture rates in established osteoporosis: A dose-response study
60. Parathyroid hormone stimulates the proliferation of cells derived from human bone
61. In vivo regulation of apoptosis in metaphyseal trabecular bone of young rats by synthetic human parathyroid hormone (1-34) fragment
62. Increased bone formation by prevention of osteoblast apoptosis with parathyroid hormone
63. Randomised controlled study of effect of parathyroid hormone on vertebral-bone mass and fracture incidence among postmenopausal women on estrogen with osteoporosis
64. Parathyroid hormone as a therapy of idiopathic osteoporosis in men: Effects on bone mineral density and bone markers
65. Water fluoridation, bone mass and fracture: A quantitative overview of the literature
66. Slow-release sodium fluoride in the management of postmenopausal osteoporosis. A randomized controlled trial
67. Effect of fluoride treatment on the fracture rate in postmenopausal women with osteoporosis
68. Prevention of early postmenopausal bone loss: Controlled 2-year study in 315 normal females
69. Fluoride salts are no better at preventing new vertebral fractures than calcium-vitamin D in postmenopausal osteoporosis: The FAVOStudy
70. Community water fluoridation, bone mineral density, and fractures: Prospective study of effects in older women
71. Failure to diagnose and treat osteoporosis in elderly patients hospitalized with hip fracture
72. Epidemiology of osteoporosis
73. Epidemiology of osteoporosis